Granulomatosis with polyangiitis (GPA), previously known as Wegener’s granulomatosis, is a rare and life-threatening disorder that restricts the blood flow to several organs, including the lungs, ...

Please provide your email address to receive an email when new articles are posted on . Systemic corticosteroid use decreased with mepolizumab treatment. Mean daily oral corticosteroid use fell by 18% ...

Please provide your email address to receive an email when new articles are posted on . Patients began with mepolizumab or benralizumab before switching to continuing with benralizumab at week 52.

WASHINGTON -- Treatment with benralizumab (Fasenra) was noninferior to mepolizumab (Nucala) for relapsing or refractory eosinophilic granulomatosis with polyangiitis (EGPA), the randomized MANDARA ...

NS-229 is currently being evaluated in a phase 2 trial in patients with eosinophilic granulomatosis with polyangiitis. The Food and Drug Administration (FDA) has granted Orphan Drug designation to ...

Eosinophilic granulomatosis with polyangiitis is an eosinophilic vasculitis. Mepolizumab, an anti–interleukin-5 monoclonal antibody, reduces blood eosinophil counts and may have value in the treatment ...

Dr. Michael Wechsler, Professor of Medicine and Director of The Asthma Institute at National Jewish Health, and International Coordinating Investigator of the MANDARA trial said: “This approval is ...

Anti-neutrophil cytoplasmic antibodies (ANCAs), such as those directed towards proteinase 3 (PR3) and myeloperoxidase (MPO), are associated with a distinct form of small-vessel vasculitis, known as ...